Premium
Chromophobe renal cell carcinoma
Author(s) -
Peyromaure Michaël,
Misrai Vincent,
Thiounn Nicolas,
Vieillefond Annick,
Zerbib Marc,
Flam Thierry A.,
Debré Bernard
Publication year - 2004
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20128
Subject(s) - medicine , chromophobe cell , pathology , renal cell carcinoma , clear cell
BACKGROUND Chromophobe renal cell carcinoma (CRCC) is often associated with a favorable prognosis. However, to the authors' knowledge, only few clinical data are available regarding this variant of tumor. In the current study, the authors report their experience with CRCC over the last 14 years. METHODS Since 1989, 61 patients have been treated at the study institution for CRCC. Tumor characteristics and patient outcome were analyzed retrospectively. Data were obtained from the patients' medical records. RESULTS The mean age of the patients was 58 years. Of the 61 tumors, 68.8% were discovered incidentally. The mean tumor size was 6.9 cm. Fifty‐seven patients (93.4%) were treated with radical nephrectomy and 4 patients (6.6%) underwent partial nephrectomy. According to the 1997 TNM classification, the pathologic tumor stage was T1 in 65.6% of cases, T2 in 31.1% of cases, and T3a in 3.3% of cases. All tumors were staged as N0M0. Nuclear grade was low (1 or 2) in 88.5% of cases. In no case of CRCC was a sarcomatoid component observed. At a mean follow‐up of 49.5 months (range, 5–135 months), no patient had experienced tumor recurrence or disease progression, and none had died of renal carcinoma. CONCLUSIONS In the authors' experience, CRCC carries an excellent prognosis, possibly due to the high rate of low‐stage and low‐grade tumors. Cancer 2004;100:1406–10. © 2004 American Cancer Society.